BeiGene Corporate Presentation

November 9, 2023

Disclosures

Certain statements contained in this presentation and in the accompanying oral presentation, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Examples of such forward-looking statements include statements regarding BeiGene's research, discovery, and pre-clinical and early-stage clinical programs and plans; recent clinical data for BeiGene's product candidates and approvals of its medicines; the conduct of late-stage clinical trials and expected data readouts; additional planned commercial product launches; and the advancement of and anticipated clinical development, regulatory milestones and commercialization of BeiGene's medicines and drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its technology and medicines; BeiGene's reliance on third parties to conduct drug development, manufacturing and other services; BeiGene's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates and achieve and maintain profitability; the impact of the COVID-19 pandemic on BeiGene's clinical development, commercial, regulatory and other operations, as well as those risks more fully discussed in the section entitled "Risk Factors" in BeiGene's most recent periodic report filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the SEC. All information in this presentation is as of the date of this presentation, and BeiGene undertakes no duty to update such information unless required by law.

Some of the clinical data in this presentation relating to BeiGene's investigational drug candidates is from pre-clinical studies or early phase, single-arm clinical trials. When such data or data from later stage trials are presented in relation to other investigational or marketed drug products, the presentation and discussion are not based on head-to-head trials between BeiGene's investigational drug candidates and other products unless specified in the trial protocol. BeiGene is still conducting pre-clinical studies and clinical trials and, as additional patients are enrolled and evaluated, data on BeiGene's investigational drug candidates may change.

This presentation and the accompanying oral presentation contain data and information obtained from third-party studies and internal company analysis of such data and information. BeiGene has not independently verified the data and information obtained from these sources. Forward-looking information obtained from these sources is subject to the same qualifications noted above.

Sustainable Competitive Advantages

Innovation with speed and lower cost to better serve patients around the world

RESEARCH	CLINICAL DEVELOPMENT	COMMERCIAL	CORNERSTONE MEDICINES	MANUFACTURING
1,100+ world-class scientists Broad preclinical programs, ~50% with first-in-class potential **$1.4B** collaboration fees	**3,000+** clinical development colleagues* in 48 regions Successful track record of developing differentiated molecules	**3,700+** competitive commercial team with ~**500** in NA/EU	**BRUKINSA and tislelizumab** Cornerstone commercial medicines with huge **global potential**	**~750** in-house people and capabilities with **cost advantage** and **agility** Small molecules and biologics **(64,000L expanding to up to 200,000L)**

*Includes full-time service professionals

Fully Integrated Global Biotech

Corporate Snapshot

$1.3B
2022 FY total product revenue (doubled vs. prior year)

17
Approved products

65+
BRUKINSA approved markets including EU

$3.2B
2023 3Q cash balance

Global Clinical Development

20K+
People enrolled in 125+ trials initiated in 45+ countries and regions

Speed and cost advantaged

Attracting Top Global Talent

10,000+
Global headcount

Global Scale Manufacturing

42-acre biologics site

Princeton Innovation Center, NJ

Expanding biologics capacity up to 200,000L

Enrollment by Geography



Leading a world-class global oncology organization with entrepreneurial culture



1,100+ innovative research scientists delivering **10 differentiated NMEs/year** including many **compelling, highly impactful programs** starting from 2024

Faster from PCC to clinical PoC by >6 months at **meaningfully reduced cost** through in-house manufacturing and CRO*-free clinical development model

---

Emerging as **heme leader** with potential best-in-class/first-in-class assets addressing broad range of malignancies, including **BTKi, BCL2i, BTK degrader**

Going beyond **immuno-oncology** in solid tumor portfolio with **oncogenic signaling targeted therapies** and **TAA-driven therapies**

NME – New Molecular Entity PCC – Preclinical Candidate PoC – Proof of Concept TAA – Tumor Associated Antigen
**Contract Research Organization*

R&D Pipeline

Heme · Solid tumors · Non-Oncology

Phase 1

Sonrotoclax — BCL2
- B-cell malignancies
- AML/MDS
- MM t(11;14)

BGB-16673 — BTK CDAC
- B-cell malignancies

BGB-21447 — next gen BCL2
- B-cell malignancies

BGB-A445 — OX40
- Solid tumors

Surzebiclimab — TIM3
- Solid tumors

BGB-15025 / 26808 — HPK1
- 15025- Solid tumors
- 26808- Solid tumors

BGB-B167 — CEA x 41BB
- CRC, NSCLC, GC

BGB-30813 — DGKζ
- Solid tumors

BGB-A3055 — CCR8
- Solid tumors

BGB-24714 — SMAC mimetic
- Solid tumors

BGB-10188 — PI3Kδ
- Solid tumors

Zanidatamab[1] — HER2 BsAb
- 1L mBC/GC

Xaluritamig[2] — STEAP1 x CD3
- mCRPC (initiation activities)

Phase 2

Zanubrutinib — BTK
- B-cell lymphoma
- CD79B R/R DLBCL
- Lupus nephritis

Sonrotoclax — BCL2
- R/R MCL
- R/R CLL
- R/R WM

Ociperlimab — TIGIT
- 1L NSCLC

LBL-007[3] — LAG3
- MSS-CRC
- 1L ESCC (initiation activities)

BGB-A445 — OX40
- Melanoma, RCC, UC

Umbrella Study — Multiple
- 1L NSCLC
- 2L+ NSCLC
- Neoadj NSCLC
- 1L HNSCC

Zanidatamab[1] — HER2 BsAb
- HER2+ 2L BTC

Phase 3

Zanubrutinib — BTK
- TN MCL
- R/R MZL, R/R FL
- pMN

Sonrotoclax — BCL2
- TN CLL (initiation activities)

Tislelizumab — PD1
- Neo/adj NSCLC*
- 1L UBC
- LA ESCC
- R/R cHL

Pamiparib — PARP
- 2L MTx gBRCAm PSOC

Ociperlimab — TIGIT
- 1L NSCLC PDL1-high

Zanidatamab[1] — HER2 BsAb
- 1L HER2+ GEA

Tarlatamab[2] — DLL x CD3
- 2L SCLC

Registration

Zanubrutinib — BTK
- TN CLL/SLL (JP)
- R/R CLL/SLL (US - PFS, JP)
- R/R FL (US, EU, CN)
- TN WM (JP)

Tislelizumab — PD1
- 1L NSCLC (EU)
- 2/3L NSCLC (EU)
- 1L Sq. NSCLC (EU)
- 1L ES-SCLC (CN)
- 1L GC/GEJC (CN)
- 1L HCC (CN)
- 1L ESCC (US)
- 2L ESCC (US)

Approved

Zanubrutinib — BTK
- TN CLL/SLL (US, EU, CN, Others)
- R/R CLL/SLL (US, EU, Others)
- R/R CLL (CN)
- R/R MCL (US, CN, Others)
- R/R MZL (US, EU, Others)
- TN WM (US, EU, CN, Others)

Tislelizumab — PD1
- 1L Non-sq. NSCLC (CN)
- 1L Sq. NSCLC (CN)
- 2/3L NSCLC (CN)
- 1L GC (CN)
- 2/3L HCC (CN)
- 1L ESCC (CN)
- 2L ESCC (EU, CN)
- 2L UBC (CN)
- 1L NPC (CN)
- 2L MSI-H/dMMR (CN)
- R/R cHL (CN)

Pamiparib — PARP
- 2L gBRCAm OC (CN)

Registration includes select accepted submissions
* Primary endpoint met
CN = China
1. Zymeworks/Jazz collaboration, BeiGene has APAC/ex Japan, AU, NZ commercial rights
2. Amgen collaboration, BeiGene has China commercial rights
3. Leads Biolabs collaboration, BeiGene has ex-China commercial rights

Emerging Leader in Hematology

Emerging as global leader in hematology with differentiated programs

BTK inhibitor

Brukinsa® 80mg zanubrutinib capsules

Superior and durable safety and efficacy across most indications, including **head-to-head vs ibrutinib.**

Broadest label
CLL/SLL, WM, MCL, MZL

FL sNDA

$15B BTKi class projected in 2028

BCL2 inhibitor

Sonrotoclax

600+ patients, with **encouraging efficacy and safety** data

Initiating a Phase 3 in **TN CLL and fast to market** Phase 2s **in MCL/WM**

Register by developing in **AML/ MDS** and **Multiple Myeloma**

Potential BIC with **ability to use by all physicians**

$**4B BCL2i market projected in 2028**

BTK CDAC

BGB-16673

100+ patients enrolled**, PoC** achieved with encouraging data

Robust development plans; fast to market indications and combinations starting in 2024

Potential in Richter's and LBCL given potency and distinct MOA

Development in BTKi resistant patients first but **expand to larger patient population**

Designed to be best-in-class BTKi with a broad set of indications around the world

Hypothesis: sustained inhibition

- Engineered to exhibit **high potency, bioavailability,** and **kinase selectivity** with aim of **reducing off-target toxicities** while maintaining continuous **high BTK inhibition**

5,200+ patients enrolled globally

- Safety and efficacy of **BRUKINSA** assessed in numerous indications **across the globe, in 35+ trials across 29 markets**

Two major Phase 3 head-to-head trials against ibrutinib

- **ORR** and **PFS** in **R/R CLL/SLL** patients shown to be superior to **ibrutinib**
- **WM** patients showed a consistent trend of **deeper** and **more durable** responses than ibrutinib

BTKi with approvals in most diseases

- Broadest label: **CLL/SLL, WM, MCL, MZL**
- sNDA in US and EU in **FL**

Expanding development program

- **Evaluating novel combinations:** with both external and internal programs across a spectrum of **hematological malignancies**

ALPINE: BRUKINSA PFS & ORR superiority to Ibrutinib in R/R CLL/SLL

2022 ASH Late Breaker & Concurrent NEJM Manuscript

BRUKINSA PFS by IRC Significantly Superior to Ibrutinib



BRUKINSA Improved PFS in Patients with del(17p)/*TP53*^{mut}



Data cutoff: 8 Aug 2022. *Brown J et al. NEJM 2022. DOI: 10.1056/NEJMoa2211582*

Data from ALPINE with longer follow up (May 2023) will be presented in oral session at ASH 2023

Separation of PFS KM curve continues

Improvement in PFS sustained

ALPINE: BRUKINSA PFS & ORR superiority to Ibrutinib in R/R CLL/SLL

Abstract Data for 2023 ASH Oral on Extended 3-Year Follow-up

Investigator-Assessed PFS (ITT Population)



ASH 2023 Abstract *Data Cutoff: 15 May 2023*

Establishing BTKi Leadership

Successful approvals in CLL are unlocking BRUKINSA's value globally and anticipated to drive revenue growth

BRUKINSA Global Revenues



- BTKi is the cornerstone therapy and the standard of care for non-Hodgkin's lymphoma
- The BTKi market was $8.4bn in 2022
- CLL is the largest indication for BTKi, accounting for 80% of the market
- Given its best-in-class profile, as demonstrated in head-to-head clinical trials for CLL, BRUKINSA is well positioned to become the leading BTKi

Sonrotoclax
Potential BIC BCL2 inhibitor with differentiated profile

More potent and specific

- **Greater potency** vs. venetoclax in preclinical models
- **Higher selectivity** could translate to improved tolerability

Enables broader usage

- Shorter **half life** vs. venetoclax and **no drug accumulation** could lead to better safety profile
- **Easier ramp-up** for increased use **by all physicians**

Improved clinical profile

- **With 600+ patients treated, clinical activity:** durable responses even at low dose levels
- Encouraging safety and tolerability in combination with BRUKINSA; fixed duration induces **deeper responses**

Development plan

- Initiating **Phase 3 registrational study** - potential to be **fixed duration SOC** globally
- **Monotherapy** potential in post-BTKi setting; **early registrations** in WM and MCL

Extends our footprint in other heme malignancies

- Expand into other hematological malignancies: by pivotal studies in **AML/MDS** in combination**, and MM with t(11,14);** compelling data in combo with dexamethasone

BGB-16673 BTK CDAC

Chimeric degradation activation compound - a novel approach to BTK pathway

CDAC platform

- **Bivalent molecule** that co-opts a process leading to degradation of target protein



BTK CDAC

- **Mutation agnostic** mechanism allows for optimal sequencing
- May provide additional **potency benefits**
- Lack of IMiD activity (vs competitors) allows for improved **safety**

Robust clinical plan

- **Two Phase 1 studies** currently enrolling (**100+** patients to date)
- Enrollment in potential **pivotal expansion cohorts** 2024
- Combination trial 2024

More heme malignancies

- **Become backbone** for patients progressing after BRUKINSA **as mono or combo with sonrotoclax**
- Degradation may **expand disease areas** where there is a clear rationale (e.g., DLBCL)

Diverse Solid Tumor Portfolio

Tevimbra: well positioned for global success

Strengthens global solid tumor portfolio by regaining global rights

Patient Impact	Data	Global Expansion and Scale
More than **750,000** patients treated commercially • 11 approved indications in China, #1 PD-1 leadership status • Now Approved in the EU for 2L ESCC	**RATIONALE-305** **1L GC/GEJC:** Met primary endpoint (OS)	**RATIONALE-302** **2L ESCC:** FDA on-site GMP inspection complete and BLA review progressing
Over **13,000 global patients** in sponsored clinical trials	**RATIONALE-312** **1L ES-SCLC:** Met primary endpoint (OS)	Under regulatory review in **11 markets** including • U.S. for both 1L and 2L ESCC • EU for NSCLC
Developing **subcutaneous injection** formulation (FIH 2023)	**RATIONALE-315** **Early-Stage NSCLC:** Met dual primary endpoints of Major Pathological Response Rate (MPR) and Event-Free Survival (EFS)	**Reduced cost** through optimization, internalization, and scale

Next Wave of Immuno-Oncology Programs

Will synergize in combination with Tevimbra

Next Wave of IO Assets

TIGIT	• Phase 3 NSCLC PDL-1+ to complete enrollment in Q1 2024
LAG3	• Phase 2 in 1L NSCLC, neoadj NSCLC, 1L HNSCC, 1L ESCC, and 1L CRC MTx • Mono, tisle combo, and tisle/TIM3 triplet dose escalation complete
TIM3	• Phase 2 in 1L HNSCC; Phase 1b in 2L+ NSCLC and HNSCC • Mono, tisle combo, and tisle/TIM3 triplet dose escalation complete
OX40	• Non-ligand blocking OX40 agonist; Phase 2 dose established • Phase 2 in 1L NSCLC, 2L+ NSCLC, UBC, RCC, and melanoma
HPK1	• Phase 2 dose established; Dose expansions enrolling in 1L NSCLC and 2L+ ESCC • 2nd generation HPK1 asset FIH achieved 3Q23
CCR8	• BIC potential – unique binding epitope, which may facilitate more potent ADCC effect • FIH achieved in 3Q23
DGKζ	• FIC potential – activator of T and NK cells • FIH achieved in 3Q23
PVRIG	• BIC potential - strong binding affinity, ligand blockade potency. FIH in 4Q23 or 1Q24 • Fc-competent which increased anti-tumor activity in pre-clinical models

Innovative Solid Tumor Portfolio

Accelerating programs in priority tumor types

NSCLC

EGFR-CDAC
panKRAS
MTA-Cooperative PRMT5
B7H3-ADC
CEA-ADC
MUC1xCD16
Claudin6xCD3

Upper GI

CEA-ADC
B7H3-ADC
CEAx4-1BB*



Colorectal

panKRAS
CEAx4-1BB*
CEA-ADC

Head and Neck

SMAC Mimetic*
B7H3-ADC

Breast

CDK4
B7H4-ADC**
BCL2i*

* In the clinic
** Exclusive global option from Duality

Growing Commercial Portfolio
With 17 Approved Assets

Product	Lead Indications	Mechanism of Action	Regulatory Status	Our Commercial Rights	Partner
Brukinsa® zanubrutinib	U.S.: CLL,R/R MCL[1], WM & R/R MZL[1]; China: R/R MCL[2], R/R CLL/SLL[2] & R/R WM[2]; EU[3]: CLL, WM & MZL	BTK inhibitor	Approved in more than 65 markets, incl. U.S., China, EU and other markets	Global	BeiGene
Tislelizumab	China:1L Squamous and Non-Squamous NSCLC, 2/3 L NSCLC, R/R classical Hodgkin's lymphoma[2], 2/3 L HCC[2], R/R PD-L1+ UC[2], 2L ESCC, MSI-H or dMMR solid tumors[2], 1L NPC, 1L G/GEJ, 1L ESCC (+chemo)	Anti-PD-1 antibody	Approved in China BLA Accepted in U.S.[4] Approved in EU	Global	BeiGene
百汇平 pamiparib	3L BRCA-mutated ovarian cancer[2]	PARP Inhibitor	Approved in China	Global	BeiGene
XGEVA® (denosumab)	Giant cell tumor of bone[8], Skeletal Related Events (SREs)[3]	Anti-RANK ligand antibody	Conditionally Approved in China*	Mainland China	AMGEN
BLINCYTO® (blinatumomab)	R/R Acute lymphocytic leukemia[3]	Anti-CD19 x anti-CD3 bispecific T-cell engager (BiTE®)	Conditionally Approved in China*	Mainland China	AMGEN
Kyprolis® (carfilzomib)	R/R Multiple myeloma[3]	Proteasome inhibitor	Approved in China^	Mainland China	AMGEN
Revlimid®	R/R adult multiple myeloma, newly diagnosed multiple myeloma, previously treated follicular lymphoma	Anti-angiogenesis, immuno-modulation	Approved in China[5]	Mainland China	Bristol Myers Squibb
Vidaza® azacitidine	Myelodysplastic syndromes, acute myeloid leukemia, chronic myelomonocytic leukemia	DNA hypomethylation	Approved in China[5]	Mainland China	Bristol Myers Squibb
sylvant® siltuximab	Idiopathic multicentric Castleman disease	IL-6 antagonist	Approved in China	Greater China	EUSA Pharma *Acquired by Recordati (2021)*
Qarziba®	High-risk neuroblastoma[2]	Anti-GD2 antibody	Approved in China	Mainland China	EUSA Pharma *Acquired by Recordati (2021)*

1. Approved under accelerated approval. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. 2. Conditionally approved. Full approval for these indications is contingent upon results from ongoing randomized, controlled confirmatory clinical trials. 3. The approval is applicable to all 27 EU member states, plus Iceland, Lichtenstein and Norway. 4. U.S.: For patients with unresectable recurrent locally advanced or metastatic ESCC after prior systemic therapy. EU: For patients with advanced or metastatic ESCC after prior systemic chemotherapy and for patients with NSCLC including: locally advanced or metastatic NSCLC after prior chemo, in combination with chemotherapy for 1L advanced or metastatic squamous NSCLC, and in combination with chemotherapy for 1L locally advanced or metastatic non-squamous NSCLC with no EGFR or ALK positive mutations. 5. Under the settlement and termination agreement with BMS, BeiGene has the right to sell remaining inventory until sold out or December 31, 2024, whichever is earlier.

3 BLINCYTO®, KYPROLIS®, and XGEVA® are registered trademarks of Amgen or its subsidiaries. *The full approval of any particular indication will depend on the results of required post-marketing study(ies) in China. ^ The full approval of pediatric indication will depend on the results of required post-marketing study in China

Growing Commercial Portfolio
With 17 approved assets

Product	Lead Indications	Mechanism of Action	Regulatory Status	Our commercial rights	Partner
POBEVCY® (Avastin biosimilar)	Colorectal, lung, glioblastoma, ovarian, and cervical cancers	Anti-VEGF antibody	Approved in China	Greater China	百奥泰 BIO-THERA
TAFINLAR® (dabrafenib)	Melanoma and BRAF V600 Mutation NSCLC	BRAF inhibitor	Approved in China	China Broad Markets[6]	NOVARTIS
MEKINIST® (trametinib)	Melanoma and BRAF V600 Mutation NSCLC	MEK inhibitor	Approved in China	China Broad Markets[6]	NOVARTIS
VOTRIENT® (pazopanib)	Advance renal cell carcinoma	VEGFR inhibitor	Approved in China	China Broad Markets[6]	NOVARTIS
AFINITOR® (everolimus)	Advance renal cell carcinoma[5], NET, SEGA and Breast cancer	mTOR inhibitor	Approved in China	China Broad Markets[6]	NOVARTIS
ZYKADIA® (ceritinib)	ALK + NSCLC	ALK inhibitor	Approved in China	China Broad Markets[6]	NOVARTIS
BAITUOWEI® (Goserelin Microspheres for Injection)	Prostate cancer for patients requiring androgen deprivation therapy (ADT)	Gonadotropin-releasing hormone (GnRH) agonist	Approved in China	Mainland China	Luye Pharma

5. Following progression on or after vascular endothelial growth factor (VEGF)-targeted therapy. 6. Rights to promote and market in China's broad markets pursuant to a Market Development Agreement with an affiliate of Novartis Pharma AG. 7. Conditionally approved. Full approval of any particular indication will depend on the results of required post-marketing study(ies) in China

Abbreviations: ALK = anaplastic lymphoma kinase; BLA = Biologics License Application; BRAF = B-rapidly accelerated fibrosarcoma; CLL = chronic lymphocytic leukemia; HCC = hepatocellular carcinoma; MCL = mantle cell lymphoma; MEK = mitogen-activated protein kinase (MAPK) / Extracellular-signal regulated kinase (ERK); MSI = microsatellite instability-high; mTOR = Mammalian target of rapamycin; MZL = marginal zone lymphoma; NET = Neuroendocrine tumors; NPC = nasopharyngeal carcinoma; NSCLC = non-small cell lung cancer; R/R = relapsed / refractory; SEGA = subependymal giant cell astrocytomas; SLL = small lymphocytic lymphoma; UC = urothelial carcinoma; VEGFR = vascular endothelial growth factor receptor; WM = Waldenström's macroglobulinemia

Growing Commercial Revenue Stream

Marketed Product Revenue



Q3 2023 Marketed Products Breakdown (by product revenue)



Positioned to Deliver on Significant Revenue Growth



Key Drivers

- Significant revenue growth driven by BRUKINSA
- Growing share of PD1/L1 class in China, expanding top leadership position
- Continued revenue growth for partner medicines
- Execution of commercial launches for late-stage pipeline
- Continued global commercial expansion

Broad Based Strategic Partnerships

We Work Collaboratively with Our Partners, Large and Small, Regionally and Globally, to Provide Innovative Medicines to Patients Faster

Multinational Corporations

AMGEN®
BLINCYTO®, KYPROLIS®, XGEVA®

Bristol Myers Squibb™
Vidaza, Revlimid

NOVARTIS
Taflinar, Mekinist, Votrient, Affinitor, Zykadia

Small and Mid-sized Companies

assemblybio
Vebicorvir

百奥泰 BIO-THERA

DualityBio 映恩生物

EUSAPharma
Acquired by Recordati (2021)
Qarziba, Sylvant

HUTCHMED

Leads Biolabs
anti-LAG-3

Luye Pharma 绿叶制药
Goserelin Microsphere

Mapkure
JV with SpringWorks

MIRATI THERAPEUTICS
Sitravatinib

Seagen
anti-CD70nt

SpringWorks THERAPEUTICS

zymeworks
Zanidatamab

Access to Innovation

INNOVENT 深信生物
Entry into LNP therapeutics

SHORELINE biosciences
Entry into cell therapy with iPSC-derived NK CAR

STRAND THERAPEUTICS
Entry into mRNA therapeutics

Clinical Supply Agreements for Combination

Abbisko 和誉
Asieris
德琪医药 ANTENGENE
微芯生物 CHIPSCREEN
ENLIVEX
Gopherwood Biotech
GENFLEET THERAPEUTICS
GUSTAVE ROUSSY
HARBOUR BIOMED
IMMIX
IMMUNE-ONC
inxmed
leaptherapeutics
Phanes Therapeutics
Prelude THERAPEUTICS
PURETECH
BIG
Simcere
TiUM

Building State-of-the-Art Manufacturing to Support Global Growth and Broad Portfolio

Multi-Functional Manufacturing Facility in Suzhou

- Commercial-scale small molecule drug products facility
- Pilot-scale biologic facility
- Suzhou Diamond Site Grand Opening in Nov 2023. Expected to increase the current small molecule manufacturing capacity in China by more than 5 times

Experienced, High-Quality Manufacturing Partners

Boehringer Ingelheim

Catalent

- Manufacturing collaborations with leading manufacturers in biologics and small molecules

State-of-the-art Biologics Manufacturing Facility in Guangzhou

- Current total capacity of 54,000L.
- Neared completion on construction of an ADC production facility and additional biologics clinical production capabilities

Future U.S. Manufacturing Facility at the Princeton West Innovation Center, NJ

- Construction underway of the first US biologic clinical & commercial production site
- 1 million+ sq ft of space for future expansion
- Grand Opening in summer 2024

BeiGene became the first company to have two sites approved in China for a biologic product (tislelizumab)

Key Catalysts

Data Readouts	**BRUKINSA (BTK inhibitor)**	ALPINE PFS long-term follow-up data at ASH 2023
	Sonrotoclax (BCL2 inhibitor)	Phase 1/2 data in TN CLL at ASH 2023
	BGB-16673 (BTK degrader)	Phase 1 data at ASH 2023
Regulatory Actions	**Tislelizumab (PD-1 antibody)**	Approval in U.S. for 2L ESCC* in 2023 or 1H 2024
		EMA approval in 1L and 2L NSCLC in 1H 2024
		Submit U.S. sBLA in 1L GC/GEJC in 2023
		Submit CN sBLA for neoadjuvant following adjuvant Stage II/IIA NSCLC
		Submit an application for marketing and manufacturing approval with the Japan PMDA for the treatment of 1L and 2L ESCC in the 1H of 2024
		Submit an sBLA with the EMA for the treatment of adult patients with 1L ESCC in 1Q 2024
	BRUKINSA	PFS superiority in U.S. CLL label in 4Q 2023; U.S. approval of sNDA in FL in March 2024
Pipeline Progress	**Sonrotoclax (BCL2 inhibitor)**	Initiate global Phase 3 trial in 1L CLL in combination with BRUKINSA in 2023
	Ociperlimab (TIGIT inhibitor)	Complete enrollment in AdvanTIG-302 trial in 1L NSCLC in 1Q 2024
	PVRIG, CDK4i	Initiate first-in-human trials in 2023 and 1Q 2024

**Original PDUFA date deferred*

Key Takeaways
Leading Global Oncology Powerhouse

- **Largest dedicated oncology R&D team**
- **Broadest reach of internally-run global clinical trials**
- **Innovative oncology pipeline with 23 development programs and 60+ discovery programs**
- **Emerging global leadership in hematology & foundation in solid tumors**

Thank you

Appendix slides follow

Condensed Consolidated Statements of Operations (U.S. GAAP)

Amounts in thousands of U.S. dollars, except for shares, American Depositary Shares (ADSs), per share and per ADS data

	Three Months Ended September 30,	
	2023	2022
	(Unaudited)	
Revenue:		
Product revenue, net	$ 595,290	$ 349,506
Collaboration revenue	186,018	38,122
Total revenues	781,308	387,628
Expenses:		
Cost of sales - products	96,309	76,543
Research and development	453,259	426,363
Selling, general and administrative	364,421	322,892
Amortization of intangible assets	1,287	187
Total expenses	915,276	825,985
Loss from operations	(133,968)	(438,357)
Interest income, net	26,649	12,759
Other income (expense), net	336,657	(125,640)
Income (loss) before income taxes	229,338	(551,238)
Income tax expense	13,925	6,318
Net income (loss)	215,413	(557,556)
Net income (loss) per share attributable to BeiGene, Ltd.:		
Basic	$ 0.16	$ (0.41)
Diluted	$ 0.15	$ (0.41)
Weighted-average shares outstanding:		
Basic	1,360,716,279	1,345,303,747
Diluted	1,390,331,833	1,345,303,747
Net income (loss) per ADS attributable to BeiGene, Ltd.:		
Basic	$ 2.06	$ (5.39)
Diluted	$ 2.01	$ (5.39)
Weighted-average ADSs outstanding:		
Basic	104,670,483	103,484,904
Diluted	106,948,603	103,484,904

1. The Company revised certain prior period financial statements for an error related to the valuation of net deferred tax assets, the impact of which was immaterial to its previously filed financial statements in the second quarter of 2022 (see "Notes to the Condensed Consolidated Financial Statements, Note 1. Description of Business, Basis of Presentation and Consolidation and Significant Accounting Policies" and "Note 2. Revision of Prior Period Financial Statements" included in our Quarterly Report on Form 10-Q for the period ended June 30, 2023, filed with the SEC).

Our Commitment to ESG

Our global strategy is focused on five areas aligned with BeiGene's mission, vision and values. These focus areas are supported by ten strategic priorities.

Our 2022 ESG Report, which was published in April, includes details about our efforts in each of these areas and describes the progress we made in 2022.

Progress in 2022

Substantial achievements across all focus areas; new goals established

Focus Area	2022 Goals	2022 Progress	New Goals
Advancing Global Health	■ Continue to invest in medicines across multiple modalities with 10 new molecules in clinic between 2022-2023	✓ Complete. Entered three new molecules in clinic	☐ 10 new molecules in clinic annually beginning in 2024
	■ Continue to seek approvals for our medicines globally	✓ Complete. BRUKINSA approved in 19 new countries and regions in 2022	
	■ Define pricing principles and affordability strategy	✓ Complete. Published BeiGene's Position on Affordability	
Empowering Our People	■ Improve colleague engagement by three percent globally versus 2020 engagement scores	✓ Complete. Improved by 7%	☐ Maintain colleague engagement scores globally versus 2022 engagement scores with a stretch goal of +3% for the 2024 engagement survey ☐ Improve work-life balance survey scores by 3%, with a stretch goal of 5% in 2023
	■ Roll out a global initiative to address work-life balance	✓ Complete. Rolling out a leadership-driven behavior change program to improve work-life balance	**By 2030:** ☐ Reach global gender parity at the VP level and above ☐ Achieve a 50% improvement in workforce diversity (underrepresented groups) company-wide at management levels in the U.S.
	■ Develop a three-year global strategy to improve DEI&B across the company	✓ Complete. 2030 goals approved by Board of Directors	☐ Continue to address the composition of the Board of Directors for gender and U.S. underrepresented groups

Progress in 2022 (cont'd)

Substantial achievements across all focus areas; new goals established

Focus Area	2022 Goals	2022 Progress	New Goals
Innovating Sustainably	■ Achieve ISO 14001 certifications for our Suzhou and Guangzhou manufacturing facilities	✓ Complete. Certification for each facility received in November 2022	☐ Set a quantitative Scopes 1 and 2 emissions goal by 2024 ☐ Set a quantitative Scope 3 emissions goal by 2025. To advance this goal, engage with two-thirds of our raw material supplier base (based on 2021 spend information) ☐ Continued from 2022: Explore the creation of a product stewardship program (This goal is in progress as we continue to evaluate internal product stewardship efforts.)
	■ Expand GHG inventory to include Scope 3 emissions	✓ Complete. Inventory compiled	
	■ Conduct a climate risk scenario analysis and assessment aligned with the Task Force for Climate-Related Financial Disclosures (TCFD) recommendations	✓ Complete. TCFD-aligned climate risk scenario analysis and assessment completed	
	■ Set a global climate strategy	✓ Complete. Strategy developed	
Supporting Communities	■ Develop a three-year patient engagement and advocacy strategy	✓ Complete. Strategy developed	☐ Spearhead multi-stakeholder solutions that empower patients and disrupt systemic access barriers by 2025 ☐ Engage employees in 10,000 hours of global volunteerism by 2023 ☐ Expand paid volunteer time-off policy globally in 2023
	■ Expand partnerships and collaborations with organizations around the world focused on health policy, equity, and patient needs	✓ Complete. Launched Talk About It: Cancer and Mental Health	
	■ Launch colleague engagement and volunteer events in the U.S., Europe, and Australia	✓ Complete. Piloted a paid volunteer time-off policy in the U.S.; organized colleague engagement events in U.S., Europe, Australia, and China	
	■ Engage employees to support organizations focused on cancer awareness raising, patient support, and research	✓ Complete. Employees participated in numerous events to support patient organizations	
Operating Responsibly	■ Become a signatory of the UN Global Compact	✓ Complete. Joined in May 2022 ✓ Participating in the UN Global Compact's SDG Ambition Accelerator	☐ Continued from 2022: Implement a third-party supplier risk management program in 2023 (Manager hired in 2022 to oversee development and implementation)